SRPK1 can promote glycogen synthase kinase-3 (GSK3β) autophosphorylation at Ser9 in a manner that is independent of its kinase activity, which ultimately confers gefitinib resistance in NSCLC by activating Wnt/β-catenin signaling. The gene discussed is SRPK1; the disease is non-small cell lung carcinoma.